Results 11 to 20 of about 25,748 (208)

Review Article: Targeting Peroxisome Proliferator-Activated Receptors in Primary Biliary Cholangitis. [PDF]

open access: yesAliment Pharmacol Ther
Peroxisome proliferator‐activated receptor (PPAR) agonists have emerged as important second‐line treatments in primary biliary cholangitis, with profiles influenced by different selectivity for α‐, δ‐ and γ‐isoforms. PPAR‐α and PPAR‐δ agonism improve cholestasis, with inflammation reduced via all isoforms. PPAR‐δ agonism also reduces pruritus.
Schattenberg JM   +8 more
europepmc   +2 more sources

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

open access: yes, 2022
Hepatology, EarlyView.
Robert J. Fontana   +6 more
wiley   +1 more source

Reduced brain UCP2 expression mediated by microRNA-503 contributes to increased stroke susceptibility in the high-salt fed stroke-prone spontaneously hypertensive rat [PDF]

open access: yes, 2017
UCP2 maps nearby the lod score peak of STR1-stroke QTL in the SHRSP rat strain. We explored the potential contribution of UCP2 to the high-salt diet (JD)-dependent increased stroke susceptibility of SHRSP.
Baima, Simona   +15 more
core   +1 more source

Fenofibrate diminishes the self-renewal and metastasis potentials of oral carcinoma stem cells through NF-κB signaling

open access: yesJournal of the Formosan Medical Association, 2022
Background/Purpose: NF-κB family of transcription factors are the major contributors to malignant tumor progression, maintenance of cancer stemness, and enhancement of chemoresistance.
Tzu-Rong Su   +7 more
doaj   +1 more source

Systematic review and network meta-analysis on the efficacy of evolocumab and other therapies for the management of lipid levels in hyperlipidemia [PDF]

open access: yes, 2017
Background: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors evolocumab and alirocumab substantially reduce low‐density lipoprotein cholesterol (LDL‐C) when added to statin therapy in patients who need additional LDL‐C reduction ...
Bray, Sarah   +13 more
core   +1 more source

Fenofibrate and losartan [PDF]

open access: yesAnnals of the Rheumatic Diseases, 2003
Should we take advantage of their uricosuric properties in clinical practice? The interesting study published in this issue of the journal by Takahashi et al sheds light on two drugs, losartan and fenofibrate, which have hypouricaemic properties, in addition to their main therapeutic effects.1 Losartan potassium is an orally active angiotensin II ...
openaire   +2 more sources

Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression

open access: yesJournal of Lipid Research, 2007
In addition to efficiently decreasing VLDL-triglycerides (TGs), fenofibrate increases HDL-cholesterol levels in humans. We investigated whether the fenofibrate-induced increase in HDL-cholesterol is dependent on the expression of the cholesteryl ester ...
Caroline C. van der Hoogt   +9 more
doaj   +1 more source

Therapeutic Effects of Fenofibrate Nano-Emulsion Eye Drops on Retinal Vascular Leakage and Neovascularization

open access: yesBiology, 2021
Macular edema caused by retinal vascular leakage and ocular neovascularization are the leading causes of severe vision loss in diabetic retinopathy (DR) and age-related macular degeneration (AMD) patients.
Li Huang   +6 more
doaj   +1 more source

Effect of diet-induced obesity on protein expression in insulin signalling pathways of skeletal muscle in male Wistar rats [PDF]

open access: yes, 2012
BACKGROUND: The prevalence of diet-induced obesity is increasing globally, and posing significant health problems for millions of people worldwide. Diet-induced obesity is a major contributor to the global pandemic of type 2 diabetes mellitus.
Abubakari, Abdul-Razak   +5 more
core   +2 more sources

Fenofibrate Improves Insulin Resistance and Hepatic Steatosis and Regulates the Let-7/SERCA2b Axis in High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease Mice

open access: yesFrontiers in Pharmacology, 2022
Fenofibrate is widely used in clinical therapy to effectively ameliorate the development of non-alcoholic fatty liver disease (NAFLD); however, its specific molecular mechanism of action remains largely unknown.
Dan Zhang   +14 more
doaj   +1 more source

Home - About - Disclaimer - Privacy